<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291499</url>
  </required_header>
  <id_info>
    <org_study_id>03CH/Ct06</org_study_id>
    <nct_id>NCT00291499</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand</brief_title>
  <official_title>Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg&#xD;
      tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint&#xD;
      osteoarthritis.&#xD;
&#xD;
      Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's&#xD;
      Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during&#xD;
      the treatment with the tested product, Condrosulf®, versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg&#xD;
      tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint&#xD;
      osteoarthritis in 160 randomised patients.&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
      Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's&#xD;
      Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during&#xD;
      the treatment with the tested product, Condrosulf®, versus placebo.&#xD;
&#xD;
      Secondary endpoints are:&#xD;
&#xD;
      Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician&#xD;
      (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of&#xD;
      Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the&#xD;
      treatment period; Other parameters:Treatment compliance; Biological markers of arthritis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Spontaneous Pain Intensity of Target Hand</measure>
    <time_frame>6 months</time_frame>
    <description>Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Index for Hand Osteoarthritis Dreiser's Score (FIHOA) in the Target Hand</measure>
    <time_frame>6 month</time_frame>
    <description>Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.&#xD;
Change calculated as difference between the month 6 value and baseline value&#xD;
Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Evaluation on Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Global impression of the efficacy judged by the Investigators at month 6 by means of a visual analogue scale from 0 (no efficacy) to 100 mm (very good efficacy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Grip Strength</measure>
    <time_frame>6 months</time_frame>
    <description>Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.&#xD;
Change calculated as difference between the month 6 value and baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Stiffness Duration</measure>
    <time_frame>6 months</time_frame>
    <description>Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of Paracetamol</measure>
    <time_frame>6 months</time_frame>
    <description>Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Chondroitin 4&amp;6 sulfate (Condrosulf)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin 4&amp;6 sulfate (Condrosulf)</intervention_name>
    <description>800 mg/day for 6 months</description>
    <arm_group_label>Chondroitin 4&amp;6 sulfate (Condrosulf)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>800 mg placebo/day for 6 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either sex&#xD;
&#xD;
          -  Aged 40 and over&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Patients fulfilling the American Congress of Rheumatology (ACR) criteria for the&#xD;
             reporting of hand OA&#xD;
&#xD;
          -  Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP&#xD;
             and 1 TMC) of the dominant hand on standard plain radiographs (&lt; 6 month).&#xD;
&#xD;
          -  Suffering from regular spontaneous pain on the dominant hand (VAS &gt; or = 40 mm at&#xD;
             inclusion time).&#xD;
&#xD;
          -  Showing a FIHOA score &gt; or = 6.&#xD;
&#xD;
          -  Having had at least two painful flares in a finger joint during the previous 12 month.&#xD;
&#xD;
          -  Patients who have signed the written informed consent for their participation in the&#xD;
             study&#xD;
&#xD;
          -  Patients able to understand and follow the protocol.&#xD;
&#xD;
          -  Patients with a satisfying health and nutritional status.&#xD;
&#xD;
          -  Female subjects of childbearing potential using, within three months prior to the&#xD;
             inclusion in the study, a reliable form of contraception during the course of the&#xD;
             study (oral contraceptive pill, intrauterine device or condoms) or female of non&#xD;
             childbearing potential (hysterectomy, bilateral ovariectomy or tubal&#xD;
             section/ligation).&#xD;
&#xD;
          -  Female subjects of childbearing potential with a negative urinary pregnancy test&#xD;
             before the inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory joint disease of other origin&#xD;
&#xD;
          -  Septic arthritis&#xD;
&#xD;
          -  Chronic inflammatory joint disease&#xD;
&#xD;
          -  Previous articular fracture of the concerned articulations&#xD;
&#xD;
          -  Use of analgesic therapy for other indications&#xD;
&#xD;
          -  Receiving oral corticosteroids&#xD;
&#xD;
          -  Mono-articular posttraumatic OA of the finger&#xD;
&#xD;
          -  Planning surgery of the hands in the following 6 months&#xD;
&#xD;
          -  Patients suffering or having suffered from secondary osteoarthritis after one of the&#xD;
             following diseases:&#xD;
&#xD;
               -  Infectious arthritis - Acromegaly&#xD;
&#xD;
               -  Ochronosis - Hemachromatosis&#xD;
&#xD;
               -  Gout - Wilson's disease&#xD;
&#xD;
               -  Chondrocalcinosis - Paget's disease&#xD;
&#xD;
               -  Osteochondrosis - Mutation of collagen&#xD;
&#xD;
               -  Genetic problems (for ex. hypermobility) - Previous joint fracture&#xD;
&#xD;
               -  Arthropathies of different aetiologies - Algodystrophy (M. Sudeck)&#xD;
&#xD;
          -  Congenital abnormalities&#xD;
&#xD;
          -  Recurrent pseudogout&#xD;
&#xD;
          -  Major dysplasias&#xD;
&#xD;
          -  Intra-articular injection in a hand joint from less than 3 months&#xD;
&#xD;
          -  Basic treatment of arthritis with symptom-modifying agents (chondroitin sulfate,&#xD;
             glucosamine sulfate, diacerhein, hyaluronic acid) in the last 3 months&#xD;
&#xD;
          -  Articular lavage in the last 3 months&#xD;
&#xD;
          -  Treatment with corticoids, by any administration route during the last month&#xD;
&#xD;
          -  Patient suffering from frequent asthma crises&#xD;
&#xD;
          -  Physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture) on the&#xD;
             hands foreseeable in the next year&#xD;
&#xD;
          -  Serious organic diseases: heart failure, renal or hepatic insufficiency, blood&#xD;
             dyscrasia, serious infection&#xD;
&#xD;
          -  Participation in other clinical trials in the two months preceding the study&#xD;
&#xD;
          -  Known or ascertained hypersensitivity to the active ingredient of the tested drug.&#xD;
&#xD;
          -  Patients refusing to sign the written informed consent form&#xD;
&#xD;
          -  Patients who do not co-operate, not respecting the protocol requirements&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cem Gabay, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUG Hôpitaux Universitaires de Genève</affiliation>
  </overall_official>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <reference>
    <citation>Lequesne M. [Symptomatic slow-action anti-arthritic agents: a new therapeutic concept?]. Rev Rhum Ed Fr. 1994 Feb;61(2):75-9. French.</citation>
    <PMID>7920505</PMID>
  </reference>
  <reference>
    <citation>Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86.</citation>
    <PMID>15751094</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76. Erratum in: Osteoarthritis Cartilage. 2007 Aug;15(8):979. DeVathaire, Florent [corrected to de Vathaire, Florent].</citation>
    <PMID>15023378</PMID>
  </reference>
  <reference>
    <citation>Cicuttini FM, Spector TD. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs Aging. 1995 May;6(5):409-20. Review.</citation>
    <PMID>7647428</PMID>
  </reference>
  <reference>
    <citation>Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am. 1993 Aug;19(3):713-24. Review.</citation>
    <PMID>8210583</PMID>
  </reference>
  <reference>
    <citation>Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 Oct;10(10):768-77.</citation>
    <PMID>12359162</PMID>
  </reference>
  <reference>
    <citation>Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung. 1991 Jul;41(7):768-72.</citation>
    <PMID>1772467</PMID>
  </reference>
  <reference>
    <citation>Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996 Aug;23(8):1385-91.</citation>
    <PMID>8856618</PMID>
  </reference>
  <reference>
    <citation>Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21.</citation>
    <PMID>9743814</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998 May;6 Suppl A:6-13.</citation>
    <PMID>9743813</PMID>
  </reference>
  <reference>
    <citation>Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30.</citation>
    <PMID>9743816</PMID>
  </reference>
  <reference>
    <citation>Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J, Masounabe-Puyanne A. [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72. French.</citation>
    <PMID>1485136</PMID>
  </reference>
  <reference>
    <citation>Bucsi L, Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998 May;6 Suppl A:31-6.</citation>
    <PMID>9743817</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998 May;6 Suppl A:39-46.</citation>
    <PMID>9743819</PMID>
  </reference>
  <reference>
    <citation>Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998 May;6 Suppl A:37-8.</citation>
    <PMID>9743818</PMID>
  </reference>
  <reference>
    <citation>Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002 Jun;21(3):231-43.</citation>
    <PMID>12111630</PMID>
  </reference>
  <reference>
    <citation>Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed. 1995 Jun;62(6 Suppl 1):43S-53S.</citation>
    <PMID>7583182</PMID>
  </reference>
  <reference>
    <citation>Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990 Nov;33(11):1601-10.</citation>
    <PMID>2242058</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <results_first_submitted>January 7, 2021</results_first_submitted>
  <results_first_submitted_qc>February 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2021</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>symptomatic OA of the hand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
          <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 800 mg placebo/day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol (PP)</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change to other therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
          <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 800 mg placebo/day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="8.5"/>
                    <measurement group_id="B2" value="63.0" spread="7.2"/>
                    <measurement group_id="B3" value="63.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Switzerland</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="4.5"/>
                    <measurement group_id="B2" value="25.0" spread="3.8"/>
                    <measurement group_id="B3" value="25.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Handedness (no. with dominant left/right hand)</title>
          <description>Number of patients with dominant left hand / dominant right hand</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Handedness (no. with target left/right hand)</title>
          <description>Number of patients with target (more painful) left hand / target (more painful) right hand</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom duration, mean +/- SD (standard deviation) years, left/right hand</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="6.3"/>
                    <measurement group_id="B2" value="6.2" spread="5.3"/>
                    <measurement group_id="B3" value="6.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="6.1"/>
                    <measurement group_id="B2" value="6.7" spread="5.7"/>
                    <measurement group_id="B3" value="6.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of painful flares in 12 months, mean +/- SD (standard deviation)</title>
          <units>flares</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="80.0"/>
                    <measurement group_id="B2" value="30.0" spread="70.3"/>
                    <measurement group_id="B3" value="32.6" spread="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of proximal interphalangeal (PIP) nodal joints, mean +/- SD (standard deviation) left/right hand</title>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="1.5"/>
                    <measurement group_id="B2" value="0.9" spread="1.2"/>
                    <measurement group_id="B3" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" spread="1.6"/>
                    <measurement group_id="B2" value="1.0" spread="1.2"/>
                    <measurement group_id="B3" value="1.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. distal interphalangeal (DIP) nodal joints, mean +/- SD (standard deviation), left/right hand</title>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="1.4"/>
                    <measurement group_id="B2" value="2.0" spread="1.4"/>
                    <measurement group_id="B3" value="2.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.3"/>
                    <measurement group_id="B2" value="2.1" spread="1.4"/>
                    <measurement group_id="B3" value="2.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's assess. of global hand pain, mean +/- SD (standard deviation), left/right/target hand</title>
          <description>Pain measured with a Visual Analogue Scale (0-100mm where 0=no pain, 100=maximum pain)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="21.0"/>
                    <measurement group_id="B2" value="42.4" spread="21.4"/>
                    <measurement group_id="B3" value="43.1" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="19.3"/>
                    <measurement group_id="B2" value="45.9" spread="19.2"/>
                    <measurement group_id="B3" value="47.3" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>target hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="14.2"/>
                    <measurement group_id="B2" value="53.6" spread="14.2"/>
                    <measurement group_id="B3" value="54.2" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional Index for Hand Osteoarthritis (FIHOA) score, mean +/- SD (standard deviation)</title>
          <description>Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="4.2"/>
                    <measurement group_id="B2" value="10.3" spread="3.8"/>
                    <measurement group_id="B3" value="10.7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of fingers with osteophytes on PIP joints, mean +/- SD (standard deviation), left/right hand</title>
          <units>number of fingers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="1.6"/>
                    <measurement group_id="B2" value="1.9" spread="1.5"/>
                    <measurement group_id="B3" value="1.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="1.5"/>
                    <measurement group_id="B2" value="1.9" spread="1.5"/>
                    <measurement group_id="B3" value="2.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of fingers with osteophytes on DIP joints, mean +/- SD (standard deviation), left/right hand</title>
          <units>number of fingers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>left hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="1.3"/>
                    <measurement group_id="B2" value="3.0" spread="1.2"/>
                    <measurement group_id="B3" value="3.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>right hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.3"/>
                    <measurement group_id="B2" value="3.1" spread="1.1"/>
                    <measurement group_id="B3" value="3.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of patients with erosive hand OA</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of patients with rhizarthrosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Global Spontaneous Pain Intensity of Target Hand</title>
        <description>Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand.</description>
        <time_frame>6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Spontaneous Pain Intensity of Target Hand</title>
          <description>Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand.</description>
          <population>ITT</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="26"/>
                    <measurement group_id="O2" value="-11.3" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Index for Hand Osteoarthritis Dreiser's Score (FIHOA) in the Target Hand</title>
        <description>Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.&#xD;
Change calculated as difference between the month 6 value and baseline value&#xD;
Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand</description>
        <time_frame>6 month</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Index for Hand Osteoarthritis Dreiser's Score (FIHOA) in the Target Hand</title>
          <description>Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.&#xD;
Change calculated as difference between the month 6 value and baseline value&#xD;
Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand</description>
          <population>ITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="5.3"/>
                    <measurement group_id="O2" value="-0.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.14</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Evaluation on Efficacy</title>
        <description>Global impression of the efficacy judged by the Investigators at month 6 by means of a visual analogue scale from 0 (no efficacy) to 100 mm (very good efficacy)</description>
        <time_frame>6 months</time_frame>
        <population>ITT (missing values where not replaced)</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Evaluation on Efficacy</title>
          <description>Global impression of the efficacy judged by the Investigators at month 6 by means of a visual analogue scale from 0 (no efficacy) to 100 mm (very good efficacy)</description>
          <population>ITT (missing values where not replaced)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>marked improvement of the clinical condition</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>slight improvement of the clinical condition</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>doubtful improvement of the clinical condition</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>Threshold p &lt;0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Grip Strength</title>
        <description>Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.&#xD;
Change calculated as difference between the month 6 value and baseline value</description>
        <time_frame>6 months</time_frame>
        <population>ITT (missing values were not replaced)</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Grip Strength</title>
          <description>Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.&#xD;
Change calculated as difference between the month 6 value and baseline value</description>
          <population>ITT (missing values were not replaced)</population>
          <units>Kg/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="6.6"/>
                    <measurement group_id="O2" value="0.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.132</p_value>
            <p_value_desc>Threshold p&lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Stiffness Duration</title>
        <description>Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value</description>
        <time_frame>6 months</time_frame>
        <population>ITT (missing values were not replaced)</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Stiffness Duration</title>
          <description>Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value</description>
          <population>ITT (missing values were not replaced)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="16.6"/>
                    <measurement group_id="O2" value="0.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>Threshold p&lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consumption of Paracetamol</title>
        <description>Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary</description>
        <time_frame>6 months</time_frame>
        <population>ITT (missing values were not replaced)</population>
        <group_list>
          <group group_id="O1">
            <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
            <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 800 mg placebo/day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Consumption of Paracetamol</title>
          <description>Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary</description>
          <population>ITT (missing values were not replaced)</population>
          <units>tablets/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.8"/>
                    <measurement group_id="O2" value="2.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.363</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chondroitin 4&amp;6 Sulfate (Condrosulf)</title>
          <description>Chondroitin 4&amp;6 sulfate (Condrosulf): 800 mg/day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 800 mg placebo/day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>synus tachicardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Leader</name_or_title>
      <organization>IBSA Institut biochimique</organization>
      <phone>0041 58360100</phone>
      <email>rd@ibsa.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

